You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 27, 2024

PLENAXIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Plenaxis patents expire, and what generic alternatives are available?

Plenaxis is a drug marketed by Speciality European and is included in one NDA.

The generic ingredient in PLENAXIS is abarelix. Additional details are available on the abarelix profile page.

Summary for PLENAXIS
Drug patent expirations by year for PLENAXIS
Recent Clinical Trials for PLENAXIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PRAECIS Pharmaceuticals Inc.Phase 4
PRAECIS Pharmaceuticals Inc.Phase 2
Speciality European Pharma LimitedPhase 3

See all PLENAXIS clinical trials

US Patents and Regulatory Information for PLENAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PLENAXIS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ⤷  Sign Up ⤷  Sign Up
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ⤷  Sign Up ⤷  Sign Up
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ⤷  Sign Up ⤷  Sign Up
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ⤷  Sign Up ⤷  Sign Up
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ⤷  Sign Up ⤷  Sign Up
Speciality European PLENAXIS abarelix INJECTABLE;INTRAMUSCULAR 021320-001 Nov 25, 2003 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PLENAXIS

See the table below for patents covering PLENAXIS around the world.

Country Patent Number Title Estimated Expiration
New Zealand 579443 Pharmaceutical formulations for sustained drug delivery ⤷  Sign Up
World Intellectual Property Organization (WIPO) 9825642 ⤷  Sign Up
Denmark 0794961 ⤷  Sign Up
European Patent Office 1188768 Peptides antagonistes de LHRH (LHRH antagonist peptides) ⤷  Sign Up
New Zealand 537042 A method for preparing a pharmaceutical formulation comprising an LHRH analogue and a carrier macromolecule ⤷  Sign Up
Australia 5699198 ⤷  Sign Up
Czech Republic 9902066 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PLENAXIS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0794961 1190014-9 Sweden ⤷  Sign Up PRODUCT NAME: ABARELIX
0794961 CR 2011 00004 Denmark ⤷  Sign Up PRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922
0794961 CA 2011 00004 Denmark ⤷  Sign Up
0794961 SPC/GB11/006 United Kingdom ⤷  Sign Up PRODUCT NAME: ABARELIX, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE - 20050922; UK PL32828/001 20100917
0794961 91857 Luxembourg ⤷  Sign Up 91857, EXPIRES: 20200922
0794961 C300484 Netherlands ⤷  Sign Up PRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922
0794961 91225 Luxembourg ⤷  Sign Up 91225, EXPIRES: 20200922
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.